Funding Rounds
Pharvaris

Pharvaris Series C (2020, $80M)

Pharvaris

Clinical stage developer focused on providing an oral treatment for patients using a bradykinin B2 receptor antagonist.

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series C

Raised Amount: $80.00M

Raised Date: 2020-01-01